Syed Akbarullah, MD
Pulmonary Disease · Henderson, NVNPI 1740221258
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (41.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Olympus Corporation Of The Americas at 42.2% of the total. 2025 is the largest year on record at $1,981, more than ten times the $44 reported in 2019.
Across 41 payments — averaging $98.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$2K
- Harmony Biosciences LLC$2K
- Abbott$149
- Intuitive Surgical$140
- Regeneron Healthcare Solutions, Inc.$139
- AstraZeneca$121
- plus $280 from 10 others
What the payments were for
- Consulting fees$1,50037%
- Travel & lodging$1,66741%
- Food & beverage$75419%
- Education$1063%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 11 | $1,698 |
| Harmony Biosciences LLC | 4 | $1,500 |
| Abbott | 1 | $149 |
| Intuitive Surgical | 1 | $140 |
| Regeneron Healthcare Solutions, Inc. | 3 | $139 |
| AstraZeneca | 5 | $121 |
| Boehringer Ingelheim | 3 | $51 |
| Boston Scientific | 3 | $47 |
| Merck | 2 | $38 |
| Inogen, Inc. | 2 | $32 |
| Amgen | 1 | $27 |
| Bayer | 1 | $25 |
| Sanofi | 1 | $17 |
| GSK | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,027 in reported general payments places this provider in the 70th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 45 | $546,541 |
| UptraviSelexipag | 28 | $413,105 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 230 | $211,570 |
| OpsumitMacitentan | 14 | $175,006 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 144 | $132,445 |
| Breo ElliptaFluticasone/Vilanterol | 97 | $59,502 |
| Spiriva RespimatTiotropium Bromide | 59 | $44,836 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $34,387 |
| SymbicortBudesonide/Formoterol Fumarate | 74 | $31,059 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $14,713 |
| Arnuity ElliptaFluticasone Furoate | 47 | $13,120 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 217 | $7,452 |
| BreynaBudesonide/Formoterol Fumarate | 22 | $5,982 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $5,582 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $5,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $51 | $625,764150 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $15 | $588,11142 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $16 | $304,488411 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $121 | $163,504218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 84 pulmonary disease providers in Nevada.
Other pulmonary disease in Henderson
- Cyriac ChemplavilHenderson$18K
- Thomson ChemplavilHenderson$17K
- Sapna BhatiaHenderson$10K
- Rajiv AmesurHenderson$9K
- Robert WillsHenderson$8K
- Michelle DanielianHenderson$2K
- Xenia SchneiderHenderson$805
- Hrishikesh KulkarniHenderson$606
- Kenneth MooneyHenderson$500
- James HsuHenderson$461
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.